iTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2014 L.P. Mpm Sells 45,698 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2014 L.P. Mpm sold 45,698 shares of iTeos Therapeutics stock in a transaction that occurred on Friday, September 17th. The stock was sold at an average price of $28.82, for a total transaction of $1,317,016.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

  • On Monday, September 20th, Bioventures 2014 L.P. Mpm sold 24,303 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.49, for a total transaction of $668,089.47.
  • On Wednesday, September 15th, Bioventures 2014 L.P. Mpm sold 24,104 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.80, for a total transaction of $670,091.20.

iTeos Therapeutics stock opened at $26.81 on Tuesday. The company’s fifty day simple moving average is $26.16 and its 200-day simple moving average is $26.37. iTeos Therapeutics, Inc. has a 12 month low of $17.43 and a 12 month high of $47.61. The stock has a market cap of $943.98 million, a P/E ratio of -13.08 and a beta of 2.43.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Thursday, August 12th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.34). On average, research analysts anticipate that iTeos Therapeutics, Inc. will post 3.22 earnings per share for the current year.

Several research firms have recently commented on ITOS. Zacks Investment Research upgraded shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 30th. SVB Leerink lowered their price target on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a report on Friday, August 13th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $47.25.

A number of large investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new stake in iTeos Therapeutics in the second quarter worth $3,666,000. Marshall Wace North America L.P. bought a new stake in iTeos Therapeutics in the second quarter worth $5,416,000. Morgan Stanley boosted its holdings in iTeos Therapeutics by 62,469.9% in the second quarter. Morgan Stanley now owns 91,352 shares of the company’s stock worth $2,344,000 after purchasing an additional 91,206 shares in the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in iTeos Therapeutics by 110,800.0% in the second quarter. Metropolitan Life Insurance Co NY now owns 6,654 shares of the company’s stock worth $171,000 after purchasing an additional 6,648 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in iTeos Therapeutics in the second quarter worth $234,000. Hedge funds and other institutional investors own 83.69% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More: How to execute a trade ex-dividend strategy?

Insider Buying and Selling by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.